The groundbreaking success of Viagra undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on off-patent versions presents a complex picture. Despite early returns were impressive, the end of patents and the emergence of less expensive alternatives have eroded the customer base. Thus, a thorough assessment of pres